Faruqi & Faruqi reminds investors of Grail class action deadline
Faruqi & Faruqi, LLP has issued a reminder to investors regarding the August 4, 2026 deadline to seek lead plaintiff status in the federal securities class action against Grail, Inc. The lawsuit alleges that Grail made false and misleading statements about its NHS-Galleri trial, leading to a 50.55% stock drop on February 20, 2026. Investors who purchased shares between May 13, 2025, and February 19, 2026, are encouraged to contact the firm to discuss their options.
*this image is generated using AI for illustrative purposes only.
Faruqi & Faruqi, LLP has reminded investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against Grail, Inc. The lawsuit alleges that the company made materially false and misleading statements regarding the progress and design of its NHS-Galleri cancer trial. Investors who purchased Grail common stock between May 13, 2025, and February 19, 2026, are encouraged to contact the firm to discuss their legal rights.
Case Background and Allegations
Grail, a commercial-stage healthcare company focused on early cancer detection, developed the Galleri test to screen for multiple cancers via blood samples. The company conducted the NHS-Galleri trial in partnership with the United Kingdom’s National Health Service (NHS) to demonstrate a reduction in late-stage (III-IV) cancers. According to the complaint, defendants made positive characterizations about the trial design and top-line results from the first screening round, asserting the three-year timeframe was sufficient to achieve the primary endpoint. However, the lawsuit contends this timeframe was inadequate, and defendants refused to provide detailed data that would have revealed the insufficient trendlines.
Stock Drop and Financial Impact
On February 19, 2026, Grail announced that the primary endpoint of statistically significant Stage III-IV reduction was not observed, attributing the outcome to the probable need for a longer follow-up period. This disclosure triggered a sharp market reaction, causing the stock price to plummet significantly in a single trading session.
| Metric | Detail |
|---|---|
| Lead Plaintiff Deadline | August 4, 2026 |
| Class Period | May 13, 2025 – February 19, 2026 |
| Share Price (Feb 19, 2026) | $101.53 |
| Share Price (Feb 20, 2026) | $50.21 |
| Single-Session Decline | 50.55% |
Legal Representation and Participation
Faruqi & Faruqi, LLP encourages investors to select qualified counsel with a proven track record. The firm has been recognized as a leading national securities law firm. Investors wishing to serve as lead plaintiff must move the Court no later than August 4, 2026. Representation is on a contingency fee basis, meaning there are no out-of-pocket costs or court expenses for shareholders. To join the class action or obtain more information, investors may visit www.faruqilaw.com/GRAL or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
How will the need for an extended follow-up period impact Grail's cash burn rate and financial runway?
What is the likelihood of the NHS continuing the partnership given the failure to meet the primary endpoint?
Will the alleged concealment of trendline data trigger additional regulatory scrutiny from the SEC beyond the class action lawsuit?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
